Stock AJW ANGES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company AnGes, Inc. Deutsche Boerse AG

Equities

AJW

JP3127700007

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG
Other stock markets
 03:41:10 2024-07-12 pm EDT 		5-day change 1st Jan Change
0.194 EUR +3.19% Intraday chart for AnGes, Inc. -1.02% -51.50%
Jan. 19 Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease MT
Jan. 18 Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan CI

Business Summary

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

Sales per Business

JPY in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
12 100.0 % 23 100.0 % +100.12%

Sales per region

JPY in Million2022Weight2023Weight Delta
Japan
100.0 %
12 100.0 % 23 100.0 % +100.12%

Managers

Managers TitleAgeSince
Tetsuji Yoneo DFI
 Director of Finance/CFO 54 12-09-30
Ei Yamada PSD
 President 74 01-04-30
Kazuo Suzuki CTO
 Chief Tech/Sci/R&D Officer 67 19-01-31
Hajime Watanabe CTO
 Chief Tech/Sci/R&D Officer - -
Jun Sakurai IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Ei Yamada PSD
 President 74 01-04-30
Makoto Hara BRD
 Director/Board Member 73 18-03-28
Junichi Komamura BRD
 Director/Board Member 74 12-02-29
Tetsuji Yoneo DFI
 Director of Finance/CFO 54 12-09-30
Norikazu Eiki BRD
 Director/Board Member 76 14-04-30
Kazuo Suzuki CTO
 Chief Tech/Sci/R&D Officer 67 19-01-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 237,368,550 230,559,958 ( 97.13 %) 92 ( 0.000039 %) 97.13 %

Shareholders

NameEquities%Valuation
Yuichiro Hayashi
0.5729 %
1,360,000 0.5729 % 372 001 €
SHIONOGI & CO., LTD.
0.5000 %
1,186,800 0.5000 % 324 625 €
Hiroshi Kawai
0.4591 %
1,089,800 0.4591 % 298 093 €
Ryuichi Morishita
0.2914 %
691,600 0.2914 % 189 173 €
Kyoko Fujita
0.2757 %
654,500 0.2757 % 179 025 €
Toshimi Otsuki
0.2738 %
650,000 0.2738 % 177 795 €
Chikanori Mizuno
0.2618 %
621,500 0.2618 % 169 999 €
Tatsuo Kagawa
0.2335 %
554,300 0.2335 % 151 618 €
SPARX Asset Management Co., Ltd.
0.0170 %
40,300 0.0170 % 11 023 €

Holdings

NameEquities%Valuation
FUNPEP COMPANY LIMITED
0.77%
 200,000 0.77% 217,580 $
FRESH TRACKS THERAPEUTICS, INC.
0.11%
 6,535 0.11% 6,208 $

Company contact information

AnGes, Inc.

Saito Bio-Incubator, 1/F 7-7-15 Saito-Asagi

567-0085, Osaka

+

http://www.anges.co.jp
address AnGes, Inc.(AJW)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.12% 126B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+25.25% 119B
ARGENX SE Stock argenx SE
+25.56% 27.95B
BIONTECH SE Stock BioNTech SE
-19.51% 20.5B
GENMAB A/S Stock Genmab A/S
-14.36% 17.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.63% 16.1B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.67% 14.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.89% 14.84B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.74% 14.38B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 4563 Stock
  4. AJW Stock
  5. Company AnGes, Inc.